Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C275632-5mg | 5mg | In stock | $77.90 | |
C275632-10mg | 10mg | In stock | $116.90 | |
C275632-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $253.90 | |
C275632-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $822.90 |
HIF-1α inhibitor
Synonyms | CAY10585;Methyl 3-[[[4-(adamantan-1-yl)phenoxy]acetyl]amino]-4-hydroxybenzoate;3-[[[4-(Adamantan-1-yl)phenoxy]acetyl]amino]-4-hydroxybenzoic Acid Methyl Ester;Methyl3-[[2-[4-(2-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate |
---|---|
Specifications & Purity | ≥97% |
Biochemical and Physiological Mechanisms | HIF-1α inhibitor (IC 50 values are 2.6 and 0.7 µM for Hep3B and AGS cell lines respectively). Suppresses transcription of HIF-1 target genes VEGF and erythropoietin at 10 µM. Attenuates hypoxia-induced ANP secretion. |
Source | Synthetic |
Storage Temp | Store at -20°C,Desiccated |
Shipped In | Ice chest + Ice pads |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | methyl 3-[[2-[4-(1-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate |
---|---|
INCHI | InChI=1S/C26H29NO5/c1-31-25(30)19-2-7-23(28)22(11-19)27-24(29)15-32-21-5-3-20(4-6-21)26-12-16-8-17(13-26)10-18(9-16)14-26/h2-7,11,16-18,28H,8-10,12-15H2,1H3,(H,27,29) |
InChi Key | BJRPPNOJYFZSLY-UHFFFAOYSA-N |
Canonical SMILES | COC(=O)C1=CC(=C(C=C1)O)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)C4 |
Isomeric SMILES | COC(=O)C1=CC(=C(C=C1)O)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)C4 |
PubChem CID | 16124726 |
Molecular Weight | 435.51 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2107841 | Certificate of Analysis | Sep 13, 2022 | C275632 |
L2107850 | Certificate of Analysis | Sep 13, 2022 | C275632 |
L2107859 | Certificate of Analysis | Sep 13, 2022 | C275632 |
L2107862 | Certificate of Analysis | Sep 13, 2022 | C275632 |
F2411027 | Certificate of Analysis | Nov 20, 2021 | C275632 |
Solubility | Soluble in DMSO to 10 mM |
---|---|
Sensitivity | heat sensitive |
1. Luo M et al.. (2022) Compression enhances invasive phenotype and matrix degradation of breast Cancer cells via Piezo1 activation.. BMC Mol Cell Biol, 23 (1). [PMID:34979904] |
2. Liu H et al.. (2022) miR-138-5p Inhibits Vascular Mimicry by Targeting the HIF-1α/VEGFA Pathway in Hepatocellular Carcinoma.. J Immunol Res, 2022 (7318950). [PMID:35669101] |
3. Tang Z et al.. (2022) Taohong Siwu Decoction Promotes Osteo-Angiogenesis in Fractures by Regulating the HIF-1α Signaling Pathway.. Evid Based Complement Alternat Med, 2022 (6777447). [PMID:36193143] |
4. Tang Z et al.. (2021) Taohong Siwu-Containing Serum Enhances Angiogenesis in Rat Aortic Endothelial Cells by Regulating the VHL/HIF-1a/VEGF Signaling Pathway.. Evid Based Complement Alternat Med, 2021 (6610116). [PMID:34853600] |